Towards AI Lesion Tracking in PET/CT Imaging: A Siamese-based CNN Pipeline applied on PSMA PET/CT Scans
This addresses the issue of operator-dependent bias in tumor response assessment for metastatic castration resistant prostate cancer patients, though it is incremental as it applies an existing method to a new domain.
The paper tackled the problem of automated lesion tracking in PET/CT imaging to assess tumor response more comprehensively by introducing a Siamese CNN approach, achieving a lesion tracking accuracy of 83% and an AUC of 0.91.
Assessing tumor response to systemic therapies is one of the main applications of PET/CT. Routinely, only a small subset of index lesions out of multiple lesions is analyzed. However, this operator dependent selection may bias the results due to possible significant inter-metastatic heterogeneity of response to therapy. Automated, AI based approaches for lesion tracking hold promise in enabling the analysis of many more lesions and thus providing a better assessment of tumor response. This work introduces a Siamese CNN approach for lesion tracking between PET/CT scans. Our approach is applied on the laborious task of tracking a high number of bone lesions in full-body baseline and follow-up [68Ga]Ga- or [18F]F-PSMA PET/CT scans after two cycles of [177Lu]Lu-PSMA therapy of metastatic castration resistant prostate cancer patients. Data preparation includes lesion segmentation and affine registration. Our algorithm extracts suitable lesion patches and forwards them into a Siamese CNN trained to classify the lesion patch pairs as corresponding or non-corresponding lesions. Experiments have been performed with different input patch types and a Siamese network in 2D and 3D. The CNN model successfully learned to classify lesion assignments, reaching a lesion tracking accuracy of 83 % in its best configuration with an AUC = 0.91. For remaining lesions the pipeline accomplished a re-identification rate of 89 %. We proved that a CNN may facilitate the tracking of multiple lesions in PSMA PET/CT scans. Future clinical studies are necessary if this improves the prediction of the outcome of therapies.